Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. ETF
  3. SLS
SLS logo

SLS

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

SLS News

Investors Focus on Middle East Developments and Job Data

4d agostocktwits

Merck's Acquisition Sparks Interest in Blood Cancer Drug Market

5d agostocktwits

SLS Shares Surge Following Merck's Tern Acquisition, Fueling Buyout Speculation in Blood Cancer Sector: Retail Investors Eye Major Pharma Contender

5d agostocktwits

SLS vs. TERN: Which Pharmaceutical Stock Offers Greater Potential as Merck Plans $6B Investment in Cancer Ahead of Keytruda Patent Expiration?

6d agostocktwits

Sellas Life Sciences Shows Significant Clinical Progress

Mar 20 2026stocktwits

SELLAS Life Sciences Reports 2025 Financials and Clinical Updates

Mar 20 2026NASDAQ.COM

Sellas Life Sciences Narrows FY25 Net Loss Amid Promising Trials

Mar 20 2026stocktwits

SELLAS Life Sciences FY 2025 Earnings Beat Expectations

Mar 19 2026seekingalpha

Sellas Life Sciences Highlights Promising Data for AML Drug SLS009 Ahead of AACR 2026

Mar 18 2026stocktwits

SELLAS Initiates Phase 2 Trial for SLS009 in AML

Mar 12 2026stocktwits

Sellas' Immunotherapy Trial Approaches Key Milestone

Mar 10 2026stocktwits

Wall Street Rebounds Amid Oil Price Volatility

Mar 10 2026stocktwits

Sellas Immunotherapy Advances with Galinpepimut-S

Mar 09 2026stocktwits

Sellas Life Sciences Stock Volatility Amid AML Summit Insights

Mar 06 2026stocktwits

Sellas Life Sciences Stock Soars Ahead of Key AML Trial Data

Mar 05 2026stocktwits

SELLAS Life Sciences Stock Surges Over 200% Amid Positive Trial Data

Mar 04 2026Benzinga